Ematologia con Trapianto, Università degli Studi di Bari "Aldo Moro"
Mediterr J Hematol Infect Dis. 2011;3(1):e2011066. doi: 10.4084/MJHID.2011.066. Epub 2011 Dec 21.
In acute promyelocytic leukemia (APL), extramedullary disease (EMD) is particularly rare and shows special clinical and biological features. It is estimated that about 3-5% of APL patients will suffer extramedullary relapse. The most common site of EMD in APL is the central nervous system (CNS). At present, there are still many issues of EMD in APL needing further clarification, including pathogenesis, risk factors, prognosis and treatment. A better understanding of the biological mechanisms underlying EMD is important to be able to devise more effective CNS prophylaxis and induction-consolidation therapeutic strategies.
在急性早幼粒细胞白血病（APL）中，髓外疾病（EMD）特别罕见，并表现出特殊的临床和生物学特征。据估计，约有 3-5%的 APL 患者会发生髓外复发。APL 中 EMD 最常见的部位是中枢神经系统（CNS）。目前，APL 中 EMD 仍有许多问题需要进一步阐明，包括发病机制、危险因素、预后和治疗。更好地了解 EMD 背后的生物学机制对于制定更有效的 CNS 预防和诱导-巩固治疗策略非常重要。
